evaluation of sensitivity of plasmodium vivax to chloroquine
نویسندگان
چکیده
background: to monitor the current response of p. vivax to chloroquine in south and southeast iran. methods : the study was undertaken from august 2004 until august 2005 at the bandar- abbas, iranshahr, nikshahr and chabahar districts. a total of 195 patients out of 225 parasitologically positive p. vivax cases completed the study .the patients were given a standard 3- day regimen of chloroquine and followed-up clinically and parasitologically according to the world health organization guideline with some modifications. results of study were addressed as mean of parasite clearance time (mpct). results : the patients responded to the regimen of chloroquine within 24-120 hours. the mpcts of p. vivax for bandar- abbas, iranshahr, nikshahr and chabahar districts were 63.05(±15.37), 56(± 21.7), 70.92 (±6.51) and 58(±14) hours, respectively and for the whole study area (south and south east of iran) was 63.50(±15.84) hours. the results of the whole studied areas indicate that difference of mpct between male and female patients is marginally significant ( p =0.05). conclusion : although, parasite clearance time for a number of cases occurred within 96 and 120 hours, no p. vivax parasites had reappeared in considered patients after day five within 28 days follow- up, reflecting that chloroquine is still an efficacious drug for the treatment of vivax malaria in the studied districts. higher mpct in nikshahr district than the other districts indicating this could be an early sign for reduced susceptibility of the parasite to the drug.
منابع مشابه
Chloroquine-Resistant Plasmodium vivax, Brazilian Amazon
To the Editor: Plasmodium vivax is the protozoan that causes the second most common form of malaria. Some resistant strains to chloroquine (CQ) occur in a few places in Asia and the Indo-Pacifi c Region (1–4). Although resistance of P. vivax to CQ has already been described in South Ameri-ca (5–7), there are limited data regarding this issue. CQ plus primaquine is the standard treatment for viv...
متن کاملRESISTANCE OF PLASMODIUM FALCIPARUM TO CHLOROQUINE IN SOUTH EASTERN IRAN
In vivo and in vitro assessments of the response of P. falciparum to chloroquine using WHO standard kits and techniques were carried out in I ran Shahr, Sistan and Baluchestan province of Iran in 1985. In the in vivo assessment, 24 malaria patients treated with chloroquine (25mg/kg over three days) were followed up for one to four weeks. The mean parasite clearance time was 4.3 days and in...
متن کاملPlasmodium vivax resistance to chloroquine in Dawei, southern Myanmar.
OBJECTIVE To assess the efficacy of chloroquine in the treatment of Plasmodium vivax malaria in in Dawei District, southern Myanmar. METHODS Enrolled patients at Sonsinphya clinic >6 months of age were assessed clinically and parasitologically every week for 28 days. To differentiate new infections from recrudescence, we genotyped pre- and post-treatment parasitaemia. Blood chloroquine was me...
متن کاملConfirmed Plasmodium vivax Resistance to Chloroquine in Central Vietnam
Plasmodium vivax resistance to chloroquine (CQ) is currently reported in almost all countries where P. vivax is endemic. In Vietnam, despite a first report on P. vivax resistance to chloroquine published in the early 2000s, P. vivax was still considered sensitive to CQ. Between May 2009 and December 2011, a 2-year cohort study was conducted in central Vietnam to assess the recommended radical c...
متن کاملin vivo susceptibility of plasmodium vivax to chloroquine in southeastern iran
background: plasmodium vivax is the predominant species causes of malaria with about 90% total annual reported malaria in iran. this study conducted to determine the susceptibility of plasmodium vivax isolates to chloroquine in sistan and balochistan province, southeastern iran. methods: a total 270 subjects with symptomatic malaria and confirmed p. vivax infection completed the designed 28-day...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
iranian journal of public healthجلد ۳۶، شماره ۳، صفحات ۶۰-۶۳
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023